進行移行上皮癌に対するMethotrexate,Vincristine,cis-Diamminedichloroplatinum,Cyclophosphamide,Adriamycin,Bleomycin併用療法(MVP-CAB療法)

Abstract

計測可能病変を有する移行上皮癌遠隔転移症例8例に対し, 第1日目MTX 20 mg/m2, CPM 500 mg/m2, VCR 1 mg/body, BLM 30 mg/body, 第2日目CDDP 50 mg/m2, 第1～3日目PRD 20 mg/bodyを投与するMVP-CAB療法を行った.その結果, PR 5例, MR 1例, NC 2例が得られ, その有効率は63%であった.本療法の主な副作用は白血球減少で, 75%の症例に白血球数2, 000/mm3以下の減少がみられたが, これに伴う重篤な併発疾患は認められなかった.その他, 胃腸症状は全例に認められたが, その程度は軽度で, 短期間の一過性のものであった

Eight patients with metastatic transitional cell carcinoma of the urinary tract were treated with the MVP-CAB regimen. All of them had bidimensionally measurable lesions. The MVP-CAB regimen consisted of cyclophosphamide 500 mg/m2, methotrexate 20 mg/m2, adriamycin 20 mg/m2, bleomycin 30 mg/body, and vincristine 1 mg/body on day 1, cis-platinum 50 mg/m2 on day 2, and prednisolone 20 mg/body on days 1-3, given every 3-4 weeks. A partial response was seen in five patients, minor response in one patient and no change in two patients. The response rate was 63% (5/8). The main toxic effect of the MVP-CAB regimen was leucopenia. In 75% of the patients there was a decrease in white blood cell count by not more than 2, 000/mm3, but no severe complication was noted. In addition, mild nausea, vomiting, mild anorexia, alopecia and fever were found. However, these symptoms were transient. One patient died of pulmonary fibrosis induced by bleomycin after 3 cycles.